Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H20N6O |
| Molecular Weight | 348.4017 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4
InChI
InChIKey=SCEVFJUWLLRELN-UHFFFAOYSA-N
InChI=1S/C19H20N6O/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26)
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed:
As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4768 |
|||
Target ID: CHEMBL2966 |
|||
Target ID: CHEMBL220 |
590.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Imizol Approved UseFor the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date1997 |
|||
| Curative | IMIDOCARB Approved UseFor treatment of babesiosis in cattle and horses Launch Date2001 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. | 1988 Jun |
|
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
| Determination of whole blood cholinesterase in different animal species using specific substrates. | 2001 Jun |
|
| Depletion and bioavailability of imidocarb residues in sheep and goat tissues. | 2002 Apr |
|
| Effects of imidocarb dipropionate in cats with chronic haemobartonellosis. | 2002 Summer |
|
| Evaluation of certain veterinary drug residues in food. | 2003 |
|
| Humoral immunity and reinfection resistance in dogs experimentally inoculated with Babesia canis and either treated or untreated with imidocarb dipropionate. | 2003 Jun 25 |
|
| Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages. | 2003 Sep 19 |
|
| [Autochthonous babesiosis in dogs in the Netherlands?]. | 2004 May 1 |
|
| First isolation and molecular characterization of Ehrlichia canis in Spain. | 2004 Nov 10 |
|
| Detection and molecular characterization of a novel large Babesia species in a dog. | 2004 Oct 5 |
|
| [A literature review of equine piroplasmosis after an episode of acute babesiosis in a Dutch Standardbred foal after a stay in Normandy]. | 2005 Dec 1 |
|
| Autochthonous canine babesiosis in The Netherlands. | 2005 Jul 15 |
|
| Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate. | 2005 Mar |
|
| Effective imidocarb dipropionate therapy for Babesia shortti in falcons. | 2006 Feb 18 |
|
| Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures. | 2006 Jun |
|
| Clinical manifestations of canine babesiosis in Hungary (63 cases). | 2006 Sep |
|
| Comparison of the efficacy of enrofloxacin, imidocarb, and oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle. | 2006 Winter |
|
| Pharmacokinetics and bioavailability of imidocarb dipropionate in swine. | 2007 Aug |
|
| Molecular characterisation of Babesia gibsoni infection from a pit-bull terrier pup recently imported into South Africa. | 2007 Mar |
|
| Evidence of an acute phase response in dogs naturally infected with Babesia canis. | 2007 Mar 31 |
|
| Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture. | 2008 Dec |
|
| An unusual form of canine babesiosis. | 2008 Mar |
|
| The clinical course of babesiosis in 76 dogs infected with protozoan parasites Babesia canis canis. | 2009 |
|
| Putative clinical piroplasmosis in a Burchell's zebra (Equus quagga burchelli). | 2009 Dec |
|
| Diagnosis and treatment of Babesia odocoilei in captive reindeer (Rangifer tarandus tarandus) and recognition of three novel host species. | 2009 Mar |
|
| Residue depletion of imidocarb in Swine tissue. | 2009 Mar 25 |
|
| Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state. | 2009 Oct 1 |
|
| Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera. | 2010 Oct 6 |
Sample Use Guides
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
||
|
WHO-VATC |
QP51AE01
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB08146MIG
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
IMIDOCARB
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
D007095
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
8USS3K0VDH
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
C83790
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
1740237
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
DB11521
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
DTXSID0048345
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
8USS3K0VDH
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
m6226
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
248-711-7
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
100000083918
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
21389
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
51804
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
27885-92-3
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
2906
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL427342
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
